{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T18:22:30Z","timestamp":1791397350340,"version":"4.3.3"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,5,13]],"date-time":"2022-05-13T00:00:00Z","timestamp":1652400000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,5,13]],"date-time":"2022-05-13T00:00:00Z","timestamp":1652400000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100010049","name":"Kingston University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010049","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Health Econ"],"published-print":{"date-parts":[[2023,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background and objective<\/jats:title>\n                <jats:p>HPV (human papillomavirus) is the virus most often responsible for sexually transmitted infections. The burden of HPV-related diseases on hospital resources represents a major public health problem. The objective of this study was to quantify the lifetime economic burden of HPV-related diseases based on hospital resources from the perspective of National Health Service (NHS) in England.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Patients\u2019 data were extracted, anonymised and aggregated by NHS digital from Hospital Episode Statistics (HES) database of patients admitted in 2015 and followed for three years. Data on hospitalizations were identified according to the International Classification of Diseases (ICD-10 CM). Health Resource Group (HRG) tariffs and National Reference Costs were used to estimate the hospitalization costs of anal, cervical, genital, oropharyngeal cancers as well as anogenital warts and cervical dysplasia.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 19,296 hospitalized patients were included in the estimation model, (39% was male and 61% female. At admission, the average age was 60 and 50\u00a0years old, respectively). Life-time costs per patients diagnosed with oropharyngeal cancer were \u00a316,911 (\u00a317,142 for male and \u00a316,334 for female), penile cancer \u00a312,539, vaginal cancer \u00a312,676, anal cancer \u00a313.773 (\u00a312,590 for male, \u00a314,525 for female). Cervical cancer accounted for \u00a312,721, whereas cervical dysplasia for \u00a33932. Resource used for hospitalized patients with anogenital warts was equal to \u00a3872 (\u00a3884 and \u00a3856 for men and women, respectively). On average, outpatient accounted for 39% of the total lifetime costs.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The results of this study highlight that a substantial amount of resources is utilized for the treatment of HPV-related diseases at hospital level in England. These measures have the potential to inform policy decisions to ensure an optimal use of the NHS resources.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s10198-022-01453-x","type":"journal-article","created":{"date-parts":[[2022,5,13]],"date-time":"2022-05-13T04:03:49Z","timestamp":1652414629000},"page":"75-80","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Hospital resource utilisation from HPV-related diseases in England: a real-world cost analysis"],"prefix":"10.1007","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9922-4810","authenticated-orcid":false,"given":"G.","family":"Fabiano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Marcellusi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F. S.","family":"Mennini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Sciattella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Favato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,13]]},"reference":[{"issue":"1","key":"1453_CR1","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1093\/infdis\/jiq016","volume":"203","author":"S Goldstone","year":"2011","unstructured":"Goldstone, S., et al.: Prevalence of and risk factors for human papillomavirus (HPV) infection among HIV-seronegative men who have sex with men. J Infect Dis 203(1), 66\u201374 (2011)","journal-title":"J Infect Dis"},{"key":"1453_CR2","doi-asserted-by":"publisher","first-page":"S52","DOI":"10.1016\/j.vaccine.2006.05.031","volume":"24","author":"AN Burchell","year":"2006","unstructured":"Burchell, A.N., et al.: Epidemiology and transmission dynamics of genital HPV infection. Vaccine 24, S52\u2013S61 (2006)","journal-title":"Vaccine"},{"issue":"3","key":"1453_CR3","doi-asserted-by":"publisher","first-page":"S15","DOI":"10.1016\/j.ygyno.2009.09.021","volume":"115","author":"X Castellsagu\u00e9","year":"2009","unstructured":"Castellsagu\u00e9, X., et al.: HPV vaccination against cervical cancer in women above 25 years of age: key considerations and current perspectives. Gynecol Oncol 115(3), S15\u2013S23 (2009)","journal-title":"Gynecol Oncol"},{"key":"1453_CR4","unstructured":"Cancer Research UK: Cervical cancer statistics. https:\/\/www.cancerresearchuk.org\/health-professional\/cancer-statistics\/statistics-by-cancer-type\/cervical-cancer#heading-Zero (2018)"},{"issue":"1","key":"1453_CR5","doi-asserted-by":"publisher","first-page":"e026292","DOI":"10.1136\/bmjopen-2018-026292","volume":"9","author":"F Pesola","year":"2019","unstructured":"Pesola, F., Sasieni, P.: Impact of screening on cervical cancer incidence in England: a time trend analysis. BMJ Open 9(1), e026292 (2019)","journal-title":"BMJ Open"},{"issue":"7","key":"1453_CR6","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/j.clinthera.2013.05.003","volume":"35","author":"G Favato","year":"2013","unstructured":"Favato, G., et al.: A novel method to value real options in health care: the case of a multicohort human papillomavirus vaccination strategy. Clin Ther 35(7), 904\u2013914 (2013)","journal-title":"Clin Ther"},{"key":"1453_CR7","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.pvr.2015.06.003","volume":"1","author":"S Hartwig","year":"2015","unstructured":"Hartwig, S., et al.: Estimation of the epidemiological burden of HPV-related anogenital cancers, precancerous lesions, and genital warts in women and men in Europe: potential additional benefit of a nine-valent second generation HPV vaccine compared to first generation HPV vaccines. Papillomavirus Res 1, 90\u2013100 (2015)","journal-title":"Papillomavirus Res"},{"key":"1453_CR8","unstructured":"Della Salute M (2017) Piano nazionale prevenzione vaccinale 2017\u20132019"},{"issue":"1","key":"1453_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12889-020-08545-4","volume":"20","author":"S Stephens","year":"2020","unstructured":"Stephens, S., et al.: The costs of treating vaginal and vulval cancer in England (2009\u20132015). BMC Public Health 20(1), 1\u20138 (2020)","journal-title":"BMC Public Health"},{"issue":"6","key":"1453_CR10","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1136\/sti.2010.048421","volume":"87","author":"S Desai","year":"2011","unstructured":"Desai, S., et al.: Genital warts and cost of care in England. Sexually Transm Infect 87(6), 464\u2013468 (2011)","journal-title":"Sexually Transm Infect"},{"issue":"4","key":"1453_CR11","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1185\/030079906X99972","volume":"22","author":"R Brown","year":"2006","unstructured":"Brown, R., et al.: Costs of detection and treatment of cervical cancer, cervical dysplasia and genital warts in the UK. Curr Med Res Opin 22(4), 663\u2013670 (2006)","journal-title":"Curr Med Res Opin"},{"key":"1453_CR12","unstructured":"N.D.H.E.S.H. database. https:\/\/digital.nhs.uk\/data-and-information\/data-tools-and-services\/data-services\/hospital-episode-statistics (2021)"},{"key":"1453_CR13","unstructured":"NHS Digital. The processing cycle and HES data quality. https:\/\/digital.nhs.uk\/data-and-information\/data-tools-and-services\/data-services\/hospital-episode-statistics\/the-processing-cycle-and-hes-data-quality (2021)"},{"key":"1453_CR14","unstructured":"National cost collection for the NHS, England. https:\/\/www.england.nhs.uk\/national-cost-collection\/#ncc1819 (2020)"},{"issue":"1","key":"1453_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13027-017-0129-6","volume":"12","author":"S Hartwig","year":"2017","unstructured":"Hartwig, S., et al.: Estimation of the overall burden of cancers, precancerous lesions, and genital warts attributable to 9-valent HPV vaccine types in women and men in Europe. Infect Agents Cancer 12(1), 1\u201310 (2017)","journal-title":"Infect Agents Cancer"},{"issue":"6","key":"1453_CR16","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1007\/s10198-019-01044-3","volume":"20","author":"F Mennini","year":"2019","unstructured":"Mennini, F., et al.: Economic burden of HPV9-related diseases: a real-world cost analysis from Italy. Eur J Health Econ 20(6), 829\u2013840 (2019)","journal-title":"Eur J Health Econ"},{"issue":"1","key":"1453_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2407-14-968","volume":"14","author":"S Abogunrin","year":"2014","unstructured":"Abogunrin, S., et al.: Prevalence of human papillomavirus in head and neck cancers in European populations: a meta-analysis. BMC Cancer 14(1), 1\u201313 (2014)","journal-title":"BMC Cancer"},{"issue":"1","key":"1453_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2458-14-1123","volume":"14","author":"ST Keeping","year":"2014","unstructured":"Keeping, S.T., et al.: The cost of anal cancer in England: retrospective hospital data analysis and Markov model. BMC Public Health 14(1), 1\u201310 (2014)","journal-title":"BMC Public Health"},{"key":"1453_CR19","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.critrevonc.2015.07.015","volume":"97","author":"RA Audisio","year":"2016","unstructured":"Audisio, R.A., et al.: Public health value of universal HPV vaccination. Crit Rev Oncol Hematol 97, 157\u2013167 (2016)","journal-title":"Crit Rev Oncol Hematol"},{"issue":"11","key":"1453_CR20","doi-asserted-by":"publisher","first-page":"e49699","DOI":"10.1371\/journal.pone.0049699","volume":"7","author":"G Baio","year":"2012","unstructured":"Baio, G., et al.: Economic burden of human papillomavirus-related diseases in Italy. PLoS ONE 7(11), e49699 (2012)","journal-title":"PLoS ONE"},{"issue":"4","key":"1453_CR21","doi-asserted-by":"publisher","first-page":"S20","DOI":"10.1016\/j.jadohealth.2010.01.016","volume":"46","author":"AK Chaturvedi","year":"2010","unstructured":"Chaturvedi, A.K.: Beyond cervical cancer: burden of other HPV-related cancers among men and women. J Adolesc Health 46(4), S20\u2013S26 (2010)","journal-title":"J Adolesc Health"},{"issue":"2","key":"1453_CR22","doi-asserted-by":"publisher","first-page":"e018359","DOI":"10.1136\/bmjopen-2017-018359","volume":"8","author":"A Marcellusi","year":"2018","unstructured":"Marcellusi, A., et al.: Economic burden of schizophrenia in Italy: a probabilistic cost of illness analysis. BMJ Open 8(2), e018359 (2018)","journal-title":"BMJ Open"},{"issue":"9","key":"1453_CR23","first-page":"1610","volume":"19","author":"A Marcellusi","year":"2015","unstructured":"Marcellusi, A., et al.: The economic burden of HCV-induced diseases in Italy. A probabilistic cost of illness model. Eur Rev Med Pharmacol Sci 19(9), 1610\u20131620 (2015)","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"2","key":"1453_CR24","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/s10198-014-0660-y","volume":"17","author":"A Marcellusi","year":"2016","unstructured":"Marcellusi, A., et al.: The direct and indirect cost of diabetes in Italy: a prevalence probabilistic approach. Eur J Health Econ 17(2), 139\u2013147 (2016)","journal-title":"Eur J Health Econ"},{"issue":"1","key":"1453_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12962-017-0073-8","volume":"15","author":"FS Mennini","year":"2017","unstructured":"Mennini, F.S., et al.: Cost-effectiveness analysis of the nine-valent HPV vaccine in Italy. Cost Eff Resour Alloc 15(1), 1\u201314 (2017)","journal-title":"Cost Eff Resour Alloc"}],"container-title":["The European Journal of Health Economics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10198-022-01453-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10198-022-01453-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10198-022-01453-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,25]],"date-time":"2023-01-25T09:32:21Z","timestamp":1674639141000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10198-022-01453-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,13]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["1453"],"URL":"https:\/\/doi.org\/10.1007\/s10198-022-01453-x","relation":{},"ISSN":["1618-7598","1618-7601"],"issn-type":[{"value":"1618-7598","type":"print"},{"value":"1618-7601","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,13]]},"assertion":[{"value":"16 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}